Earlier this year, the American Society of Nephrology (ASN) launched “We’re United 4 Kidney Health,” an initiative that repositions nephrology as a specialty that embraces kidney health through early intervention, transplantation, innovation and patient choice, and equity. We’re United 4 Kidney Health presents a rallying cry that shows how the kidney community can advance the field by embracing four priorities:
INTERVENE EARLIER to prevent, diagnose, coordinate care, and educate.
TRANSFORM TRANSPLANT and increase access to donor kidneys.
ACCELERATE INNOVATION and expand patient choice.
ACHIEVE EQUITY and eliminate disparities.
ASN is committed to a world without kidney diseases, and the society
Monoclonal immunoglobulin (Ig)/light chain (AL)-associated systemic amyloidosis is caused by clonal plasma cells producing abnormal Ig light chains that misfold into amyloid fibrils, deposit in vital organs, disrupt organ function, and if left untreated, ultimately result in death. Given its insidious onset and nonspecific symptomatology, delay in AL amyloidosis diagnosis is unfortunately typical (1). The prognosis of patients is primarily driven by an advanced organ, specifically cardiac involvement (2). The kidney is affected in 70% of patients manifesting as proteinuria and progressive kidney dysfunction, which leads to the need for kidney replacement therapy in 15%–30% of
Jorge Cerdá, Samir M. Parikh, Jay Koyner, Anitha Vijayan, Erin Barreto, and on behalf of the initiative
In hospitals and in the community, the incidence of acute kidney injury (AKI) is high and rising worldwide. At the societal level, AKI is increasingly recognized as a major public health burden (1). For the individual patient, severe AKI is a life-altering event with profound immediate and future consequences. Recently, the COVID-19 pandemic has highlighted the impact of AKI in hospitalized patients with SARS-CoV-2 infection.
AKI is not a single disease, but a syndrome caused by multiple mechanisms in patients with different comorbidities and several potential treatment targets. By developing the AKI!Now initiative, ASN is committed
Jeffrey Silberzweig, Alan S. Kliger, and Susan Stark
The COVID-19 pandemic has been devastating for kidney patients and challenging for nephrologists, nurses, and other caregivers. However, in the kidney community, it has led to collaborations that reduced the impact of COVID-19—collaborations that promise to serve kidney patients and professionals long into the future.
In March 2020, ASN formed the COVID-19 Response Team as a forum to gather accurate, unbiased information from reliable sources and to share it broadly with the kidney community, nationally, and regionally. The pandemic's ever-changing realities required continuous refinement, underscored the need to learn from one another's experience, and offered the opportunity to build on
The past 18 months have brought to the kidney community an explosion of innovative therapies that have ushered in a wave of promise for the treatment of diabetic kidney diseases (DKDs).
Globally, 476 million adults are living with diabetes (1), of whom 40% will develop DKD (2). The impact of DKD on patient quality of life is extensive, and the care of these patients is complex, requiring the thoughtful intersection of specialties and ongoing communication for quality management of care.
To date, the standard of care for treatment of DKD has been an angiotensin-converting enzyme (ACE)
With increasing uncertainties around variants of the COVID-19 virus, ASN canceled plans for the in-person component of ASN Kidney Week 2021 in San Diego, CA. Putting health and safety first, ASN firmly believes this decision is in the best interest of meeting participants, stakeholders, partners, and—most important—the millions of people who have entrusted us with their healthcare.
Please refer to the Kidney Week FAQs for more information.
All meeting content will be available to all participants on the Kidney Week platform until Friday, January 7, 2022. In late January 2022, this content
The Belding H. Scribner Award will be tendered on Saturday, November 6, to Jonathan Himmelfarb, MD, FASN, for his career-long contributions to the practice of nephrology. Dr. Himmelfarb is professor of medicine, adjunct professor of bioengineering, director of the Kidney Research Institute, and co-director of the Center for Dialysis Innovation at the University of Washington in Seattle. He also holds the Joseph W. Eschbach, MD, Endowed Chair in Kidney Research.
Established in 1995, the Belding H. Scribner Award is presented to individuals who have made outstanding contributions to the care of patients with kidney disorders or
Suzanne M. Boyle, Stephen M. Sozio, Andrew S. Parsons, and Karen M. Warburton
Clinical reasoning is the process by which clinicians gather, interpret, and synthesize data to arrive at a diagnosis and make management decisions. Research in this field aims to: 1) understand decision-making under conditions of uncertainty and 2) promote systematic approaches to reasoning that minimize cognitive bias and reduce medical error (1, 2). Although most early-stage clinicians develop reasoning skills through repeated clinical exposure, many benefit from more explicit instruction (Figure 1) (3, 4).
Clinical decision-making pathway
These steps are informed by non-analytical and analytical processes. The non-analytical process
Vascular endothelial growth factor (VEGF or VEGF-A) is a powerful vascular growth factor and is important for maintaining glomerular health. Clinically, an anti-VEGF state induces glomerular injury. For example, excess placental production of soluble Fms-like tyrosine kinase (sFLT1), a decoy receptor for VEGF, causes preeclampsia. Moreover, patients treated with VEGF inhibitors show glomerular pathologies and hypertension. Recently, Wewers et al. report a comprehensive review on the role of circulating sFLT1 in kidney diseases other than preeclampsia (1).
The kidney vasculature is particularly dependent on VEGF-VEGF receptor 2 (VEGFR2) signaling for its development and maintenance (1,